During Q4 2018 the big money sentiment decreased to 1.21. That’s change of 0.20, from 2018Q3’s 1.41. 13 investors sold all, 64 reduced holdings as Pacira Pharmaceuticals, Inc. ratio dropped. 56 grew holdings while 37 funds acquired holdings. Funds hold 39.33 million shares thus 0.69% less from 2018Q3’s 39.60 million shares.
99,289 are owned by Jacobs Levy Equity Mngmt. Acadian Asset Management Limited Liability Corporation invested 0.01% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Oak Ridge Invs Ltd reported 0.59% stake. Jane Street Gp Limited Company owns 18,798 shs. 393,035 were accumulated by Deutsche State Bank Ag. Elk Creek Prns Ltd Liability owns 1.91% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 536,194 shs. 2.86 million are held by Healthcor Mngmt L P. Principal Financial owns 11,961 shs. Tudor Invest Et Al invested in 72,968 shs or 0.06% of the stock. San Francisco Sentry Invest Gp (Ca) owns 12 shs. Citigroup has invested 0% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Hightower Advisors Limited Liability has invested 0% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Parametric Associates Limited Liability Company invested in 109,889 shs. Clearbridge Invests Llc reported 0.05% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). California Pub Employees Retirement reported 0% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).
Pacira Pharmaceuticals, Inc. registered $7.33 million net activity with 3 insider purchases and 6 sales since November 2, 2018. 14,527 shs valued at $680,496 were sold by Wicki Andreas on Wednesday, December 12. On Monday, November 19 $207,810 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was bought by PACE GARY W. $710,801 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by STACK DAVID M. On Wednesday, March 6 Kronenfeld Mark A. bought $66,244 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 1,700 shs.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)’s earnings report is anticipated by WallStreet on May, 2, as reported by Faxor. Analysts predict $-0.02 EPS, which is $0.16 up or 88.89 % from 2018’s $-0.18 EPS. -107.14 % negative EPS growth is what Wall Street’s sees after $0.28 reported EPS previous quarter. The stock decreased 0.05% or $0.02 during the last trading session, hitting $37.77.Pacira Pharmaceuticals, Inc. has volume of 243,938 shares. Since April 14, 2018 PCRX has risen 24.65% and is uptrending. PCRX outperformed by 20.28% the S&P500.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage
In total 8 analysts cover Pacira Pharmaceuticals (NASDAQ:PCRX). “Buy” rating has 3, “Sell” are 2, while 3 are “Hold”. 38% are bullish. 12 are the (NASDAQ:PCRX)’s analyst reports since November 2, 2018 according to StockzIntelligence Inc. The company rating was maintained by JP Morgan on Friday, November 2. On Thursday, February 28 the firm earned “Sell” rating by Mizuho. On Friday, February 1 the firm earned “Underperform” rating by Mizuho. On Wednesday, March 6 the company was maintained by Mizuho. On Friday, November 2 the company was maintained by JMP Securities. The company rating was maintained by BMO Capital Markets on Friday, March 1. In Friday, March 1 report H.C. Wainwright maintained it with “Buy” rating and $60 target. On Friday, November 2 BMO Capital Markets maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating. BMO Capital Markets has “Market Perform” rating and $47 target. The company rating was maintained by Wedbush on Monday, March 4. On Tuesday, March 5 the stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Hold” rating given by Canaccord Genuity.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States.The firm is valued at $1.56 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.Last it reported negative earnings. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.
For more Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news announced briefly go to: Globenewswire.com, Nasdaq.com, Seekingalpha.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results – GlobeNewswire” announced on November 01, 2018, “Pacira to Report 2018 Financial Results on Thursday February 28, 2019 – Nasdaq” on February 21, 2019, “Pacira completes MyoScience takeover – Seeking Alpha” with a publish date: April 09, 2019, “Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control – GlobeNewswire” and the last “Pacira’s Exparel shows treatment benefit in C-section patients – Seeking Alpha” with publication date: December 12, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.